Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells $350,929.18 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Timothy Williams sold 42,434 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total transaction of $350,929.18. Following the completion of the sale, the senior vice president owned 377,450 shares in the company, valued at approximately $3,121,511.50. The trade was a 10.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vanda Pharmaceuticals Trading Down 0.3%

Shares of VNDA stock opened at $7.89 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $466.38 million, a price-to-earnings ratio of -2.12 and a beta of 0.55. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $9.60. The stock’s 50-day moving average price is $7.60 and its 200-day moving average price is $6.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. The firm had revenue of $57.22 million for the quarter, compared to analysts’ expectations of $59.28 million. Equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VNDA. B. Riley Financial increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Truist Financial initiated coverage on shares of Vanda Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright raised their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Finally, Jefferies Financial Group increased their price objective on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research note on Wednesday, December 31st. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.90.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VNDA. Vanguard Group Inc. grew its holdings in Vanda Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock worth $17,900,000 after purchasing an additional 14,336 shares during the last quarter. Millennium Management LLC boosted its holdings in Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after acquiring an additional 1,470,898 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter worth about $17,626,000. Geode Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 4.8% during the second quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after acquiring an additional 77,997 shares during the last quarter. Finally, Krensavage Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 15.2% during the third quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after acquiring an additional 155,505 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.